Targeted dosing to treat pediatric inflammatory bowel disease is challenging because dosing guidelines are based on data gathered from adult subjects of clinical trials. Patients’ families and health care organizations also incur high costs and must try to balance potential benefits against risks of ongoing monitoring.
AMA J Ethics. 2018; 20(9):E841-848. doi:
10.1001/amajethics.2018.841.
Amy Scharf(理学硕士), Louis Voigt(医学博士), Santosha Vardhana(医学博士、哲学博士), Konstantina Matsoukas(图书情报硕士), Lisa M. Wall(哲学博士、注册护士、临床护理专家、高级肿瘤临床护理专家、已获认证的医疗保健伦理顾问), Maria Arevalo(注册护士、肿瘤专科护士), and Lisa C. Diamond(医学博士、公共卫生硕士)
AMA J Ethics. 2021; E97-108. doi:
10.1001/amajethics.2021.97.
Amy Schart, MS, Louis Voigt, MD, Santosha Vardhana, MD, PhD, Konstantina Matsoukas, MLIS, Lisa M. Wall, PhD, RN, CNS, AOCNS, HEC-C, María Arévalo, RN, OCN, and Lisa C. Diamond, MD, MPH
AMA J Ethics. 2021; E97-108. doi:
10.1001/amajethics.2021.97.